Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
about
Maintenance chemotherapy for ovarian cancerMaintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-AnalysisMonitoring mortality in forced migrants--can Bayesian methods help us to do better with the (little) data we have?Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.Clinical trials and progress with paclitaxel in ovarian cancerPractical considerations in ovarian cancer chemotherapy.Clinical utility of targeted treatments in the management of epithelial ovarian cancer.The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.Are there candidates for high-dose chemotherapy in ovarian carcinoma?Ovarian cancer treatment: The end of empiricism?Estimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy.Should studies of maintenance therapy be maintained in women with ovarian cancer?GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysisClinically relevant anticancer polymer Paclitaxel therapeutics.S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.Taxanes: their impact on gynecologic malignancy.Metronomics as maintenance treatment in oncology: time for chemo-switch.Abagovomab for ovarian cancer.Current and future directions of clinical trials for ovarian cancer.Ovarian cancer stem cells: elusive targets for chemotherapy.Olaparib, PARP1 inhibitor in ovarian cancer.Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.Maintenance chemotherapy in the management of epithelial ovarian cancer.Bayesian survival analysis in clinical trials: What methods are used in practice?Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.Dangers of "confirmatory" cancer trials that fail to actually test the original hypothesis.Emerging drugs for ovarian cancerAntiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trialsTargeted treatment of advanced ovarian cancer: spotlight on rucaparib
P2860
Q24201758-49EFB7A7-0367-4E26-847A-4B50BE550CA1Q26781561-B7039F52-D524-4376-A3F3-DA114FB975DCQ31008727-2879A47C-6EB5-4A11-9DBD-54DC91DB9AE7Q31047715-6A0E87DE-ECA9-4617-9011-AF829019B9B7Q34510070-1B310C9C-7DB8-4432-9E6A-F33CEAE0C4D4Q35076260-E8341CE9-9843-4AD4-9B5B-48D7071DDA18Q36171268-B7CC308C-64EA-4E62-B348-89E56817A8CCQ36242803-71CFAB3D-4374-432F-9C87-172995088495Q36468856-0845B10B-C87E-402E-8559-3D4EAC30CF56Q36554444-91BDB2AF-608F-44B4-8EF9-AB19960F4A53Q36584405-1BCF35BD-857C-4DD8-8B14-BEFACD553D40Q36811358-1F89D343-B8D1-4D40-9ABA-E73731771F5DQ36817461-43A1E335-28DC-4ED4-B399-B3688D7A3FE9Q36962482-3EE3C15D-70D3-4234-BE25-856B7B0B91E8Q37086928-CD85F1FD-1B34-4093-B610-957257A0865FQ37129736-98454468-6AFB-443D-8204-DDABE465E804Q37383301-143E5E52-6B21-462A-8952-3C8C96E394A7Q37692801-3FBA3404-9FF8-4343-BF71-7C9645A0FBAAQ37707573-1B0909EC-94A1-4CE4-8B7F-D589BF543675Q37829443-F584DDC1-B8DE-43D0-943D-98288A84995DQ37832932-EF096E08-569D-4635-88F7-8A9D15DDBF38Q38013671-78C23E75-4249-48A1-B4FF-0173EF10F5ABQ38025738-A1195D0D-69D7-46B1-9700-464BDFCF6651Q38222277-9C8E769E-EDCF-44AF-84F1-5B9085027FDAQ38310412-5E0A0F3D-5161-49BE-B546-6F2156DFD790Q38978314-C55CCB29-D7B2-4AD0-9DD1-13DE4991484AQ41524271-ABEF77F2-DB04-4796-A8CD-818B8D1E35E4Q41616541-93D3A85A-4312-459C-A354-F74898CDC6BFQ51753941-D21553C0-FB73-494D-BD33-5BD7A75E7D43Q57903790-EE74F33B-80A6-4F1F-A17C-A9EFC3D5C89CQ58706801-232E94C9-1D43-4EF1-9200-52EC42AFFA1AQ59125756-18D61DAB-8484-4653-A437-4EB4A84A3143
P2860
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Phase III trial of observation ...... lts of the After-6 protocol 1.
@en
Phase III trial of observation ...... lts of the After-6 protocol 1.
@nl
type
label
Phase III trial of observation ...... lts of the After-6 protocol 1.
@en
Phase III trial of observation ...... lts of the After-6 protocol 1.
@nl
prefLabel
Phase III trial of observation ...... lts of the After-6 protocol 1.
@en
Phase III trial of observation ...... lts of the After-6 protocol 1.
@nl
P2093
P50
P921
P356
P1476
Phase III trial of observation ...... lts of the After-6 protocol 1.
@en
P2093
After 6 Italian Cooperative Group
Amalia Carpi
Dionyssios Katsaros
Giovanni Scambia
Giuseppe Favalli
Michela Ballardini
Pierluigi Benedetti Panici
Sergio Pecorelli
P304
P356
10.1200/JCO.2009.21.9691
P407
P577
2009-08-24T00:00:00Z